146 related articles for article (PubMed ID: 24480527)
1. Clinically relevant quality assurance (QA) for prostate RapidArc plans: gamma maps and DVH-based evaluation.
Cozzolino M; Oliviero C; Califano G; Clemente S; Pedicini P; Caivano R; Chiumento C; Fiorentino A; Fusco V
Phys Med; 2014 Jun; 30(4):462-72. PubMed ID: 24480527
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of volumetric modulated arc therapy patient specific QA results to multileaf collimator errors and correlation to dose volume histogram based metrics.
Coleman L; Skourou C
Med Phys; 2013 Nov; 40(11):111715. PubMed ID: 24320423
[TBL] [Abstract][Full Text] [Related]
3. Initial experience of ArcCHECK and 3DVH software for RapidArc treatment plan verification.
Infusino E; Mameli A; Conti R; Gaudino D; Stimato G; Bellesi L; D'Angelillo RM; Ramella S; Benassi M; Trodella L
Med Dosim; 2014; 39(3):276-81. PubMed ID: 25088815
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment patient-specific IMRT quality assurance: a correlation study between gamma index and patient clinical dose volume histogram.
Stasi M; Bresciani S; Miranti A; Maggio A; Sapino V; Gabriele P
Med Phys; 2012 Dec; 39(12):7626-34. PubMed ID: 23231310
[TBL] [Abstract][Full Text] [Related]
5. Moving from gamma passing rates to patient DVH-based QA metrics in pretreatment dose QA.
Zhen H; Nelms BE; Tome WA
Med Phys; 2011 Oct; 38(10):5477-89. PubMed ID: 21992366
[TBL] [Abstract][Full Text] [Related]
6. Clinically relevant quality assurance for intensity modulated radiotherapy plans: gamma maps and DVH-based evaluation.
Caivano R; Califano G; Fiorentino A; Cozzolino M; Oliviero C; Pedicini P; Clemente S; Chiumento C; Fusco V
Cancer Invest; 2014 Mar; 32(3):85-91. PubMed ID: 24499109
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of one algorithm used to modify a planned DVH with data from actual dose delivery.
Ma T; Podgorsak MB; Kumaraswamy LK
J Appl Clin Med Phys; 2016 Sep; 17(5):273-282. PubMed ID: 27685140
[TBL] [Abstract][Full Text] [Related]
8. DVH analysis using a transmission detector and model-based dose verification system as a comprehensive pretreatment QA tool for VMAT plans: Clinical experience and results.
Mohamed Yoosuf AB; AlShehri S; Alhadab A; Alqathami M
J Appl Clin Med Phys; 2019 Nov; 20(11):80-87. PubMed ID: 31605456
[TBL] [Abstract][Full Text] [Related]
9. Volumetric-modulated arc therapy: effective and efficient end-to-end patient-specific quality assurance.
O'Daniel J; Das S; Wu QJ; Yin FF
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1567-74. PubMed ID: 21470797
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric evaluation of MapCHECK 2 and 3DVH in the IMRT delivery quality assurance process.
Song JY; Kim YH; Jeong JU; Yoon MS; Ahn SJ; Chung WK; Nam TK
Med Dosim; 2014; 39(2):134-8. PubMed ID: 24332483
[TBL] [Abstract][Full Text] [Related]
11. Patient specific pre-treatment QA verification using an EPID approach.
Vazquez Quino LA; Chen X; Fitzpatrick M; Shi C; Stathakis S; Gutierrez A; Esquivel C; Mavroidis P; Alkhatib H; Papanikolaou N
Technol Cancer Res Treat; 2014 Feb; 13(1):1-10. PubMed ID: 23819492
[TBL] [Abstract][Full Text] [Related]
12. A clinically relevant IMRT QA workflow: Design and validation.
Stambaugh C; Ezzell G
Med Phys; 2018 Apr; 45(4):1391-1399. PubMed ID: 29481698
[TBL] [Abstract][Full Text] [Related]
13. Patient-specific 3D pretreatment and potential 3D online dose verification of Monte Carlo-calculated IMRT prostate treatment plans.
Boggula R; Jahnke L; Wertz H; Lohr F; Wenz F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1168-75. PubMed ID: 21093168
[TBL] [Abstract][Full Text] [Related]
14. Clinical introduction of a linac head-mounted 2D detector array based quality assurance system in head and neck IMRT.
Korevaar EW; Wauben DJ; van der Hulst PC; Langendijk JA; Van't Veld AA
Radiother Oncol; 2011 Sep; 100(3):446-52. PubMed ID: 21963288
[TBL] [Abstract][Full Text] [Related]
15. Impact of plan parameters on the dosimetric accuracy of volumetric modulated arc therapy.
Masi L; Doro R; Favuzza V; Cipressi S; Livi L
Med Phys; 2013 Jul; 40(7):071718. PubMed ID: 23822422
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive and clinical-oriented evaluation criteria based on DVH information and gamma passing rates analysis for IMRT plan 3D verification.
Yi X; Lu WL; Dang J; Huang W; Cui HX; Wu WC; Li Y; Jiang QF
J Appl Clin Med Phys; 2020 Aug; 21(8):47-55. PubMed ID: 32436351
[TBL] [Abstract][Full Text] [Related]
17. Correlation between gamma index passing rate and clinical dosimetric difference for pre-treatment 2D and 3D volumetric modulated arc therapy dosimetric verification.
Jin X; Yan H; Han C; Zhou Y; Yi J; Xie C
Br J Radiol; 2015 Mar; 88(1047):20140577. PubMed ID: 25494412
[TBL] [Abstract][Full Text] [Related]
18. Retrospective review of locally set tolerances for VMAT prostate patient specific QA using the COMPASS(®) system.
Sdrolia A; Brownsword KM; Marsden JE; Alty KT; Moore CS; Beavis AW
Phys Med; 2015 Nov; 31(7):792-7. PubMed ID: 25886957
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of DVH-based treatment plan verification in addition to gamma passing rates for head and neck IMRT.
Visser R; Wauben DJ; de Groot M; Steenbakkers RJ; Bijl HP; Godart J; van't Veld AA; Langendijk JA; Korevaar EW
Radiother Oncol; 2014 Sep; 112(3):389-95. PubMed ID: 25154319
[TBL] [Abstract][Full Text] [Related]
20. Can knowledge-based DVH predictions be used for automated, individualized quality assurance of radiotherapy treatment plans?
Tol JP; Dahele M; Delaney AR; Slotman BJ; Verbakel WF
Radiat Oncol; 2015 Nov; 10():234. PubMed ID: 26584574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
